Table 1:
Preoperative data
| Age, years ± SD (range) | 71.18 ± 7.7 (39–89) |
| <70 | 54 (27%) |
| 70–79 | 126 (63%) |
| >80 | 20 (10%) |
| Gender, M/F | 115/85 (57.5/42.5%) |
| BMI ± SD (range) | 28.41 ± 4.8 (18.1–43.8) |
| BSA, m2 ± SD (range) | 1.86 ± 0.2 (1.5–2.6) |
| NYHA class | |
| I | 2 (1%) |
| II | 48 (24%) |
| III | 118 (59%) |
| IV | 32 (16%) |
| Angina pectoris | 72 (36%) |
| Syncope | 6 (3%) |
| LVEF | |
| <20% | 3 (1.5%) |
| 21–30% | 8 (4%) |
| 31–50% | 48 (24%) |
| >50% | 141 (70.5%) |
| Urgent procedures | 7 (3.5%) |
| Hypertension | 144 (72%) |
| Diabetes | 80 (40%) |
| Dyslipidemia | 74 (37%) |
| COPD | 20 (10%) |
| Chronic renal disease | 22 (11%) |
| Chronic atrial fibrillation | 34 (17%) |
| Coronary artery disease | 70 (35%) |
| Redo | 13 (6.5%) |
| Aortic lesion | |
| Stenosis | 129 (64.5%) |
| Insufficiency | 27 (13.5%) |
| Mixed | 40 (20%) |
| Prosthetic failure | 4 (2%) |
| Aetiology | |
| Degenerative | 110 (55%) |
| Congenital | 57 (28.5%) |
| Rheumatic | 12 (6%) |
| Endocarditis | 13 (6.5%) |
| Prosthetic failure | 4 (2%) |
| Undefined | 4 (2%) |
| Valve gradient (mmHg) ± SD | |
| Mean | 48.1 ± 3.3 |
| Peak | 73.9 ± 5.4 |
| Surgery | |
| Valve size (mm) | |
| 19 mm | 33 (16.5%) |
| 21 mm | 81 (40.5%) |
| 23 mm | 59 (29.5%) |
| 25 mm | 23 (11.5%) |
| 27 mm | 4 (2%) |
| Concomitant procedures | 87 (43.5%) |
| Coronary artery bypass grafting | 55 (27.5%) |
| Mitral valve replacement | 9 (4.5%) |
| Mitral valve repair | 8 (4%) |
| Tricuspid annuloplasty | 4 (2%) |
| Ascending aorta aneurysm | 11 (5.5%) |
M/F: male/female; BMI: body mass index; BSA: body surface area; NYHA: New York Heart Association; LVEF: left ventricular ejection fraction; COPD: chronic obstructive pulmonary disease.